B. Riley lowered the firm’s price target on Viridian Therapeutics (VRDN) to $25 from $29 and keeps a Buy rating on the shares. Viridian competitor Acelyrin (SLRN) reported preliminary proof-of-concept data for its insulin like growth factor 1 receptor, lonigutamab, though the sample size is too small to draw definitive conclusions regarding the superiority or inferiority of lonigutamab over competing assets, the analyst tells investors in a research note. The firm anticipates Viridian’s upcoming pivotal studies will successfully meet key endpoints.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics, Inc. (VRDN) Q4 Earnings Cheat Sheet
- Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo
- Viridian Therapeutics price target raised to $40 from $39 at Wedbush
- Viridian Therapeutics price target lowered to $37 from $38 at JMP Securities
- Viridian Therapeutics expects cash to fund operations into second half of 2026